PRESS RELEASE published on 06/13/2025 at 01:25, 11 months ago Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Moderna receives FDA approval to expand indication of mRESVIA vaccine for adults aged 18-59 at increased risk of RSV, based on Phase 3 study results showing safety and efficacy FDA Approval Moderna RSV Vaccine Phase 3 Study MRESVIA
BRIEF published on 06/11/2025 at 13:05, 11 months 1 day ago Moderna to Present at Barclays Science Call Series MRNA Technology Presentation Moderna Barclays Investor Event
BRIEF published on 06/11/2025 at 13:05, 11 months 1 day ago Moderna participera à la série d'appels scientifiques de Barclays Presentation Barclays Moderne Événement Pour Les Investisseurs Technologie De L'ARNm
PRESS RELEASE published on 06/11/2025 at 13:00, 11 months 1 day ago Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 Moderna, Inc. announces participation in Barclays Speaking the Science Call Series on June 16th at 10:00am ET. Webcast available on Moderna's website Webcast MRNA Medicine Moderna Barclays Investor Event
BRIEF published on 05/31/2025 at 06:21, 11 months 13 days ago Moderna's mNEXSPIKE COVID-19 Vaccine Secures FDA Approval FDA Approval COVID-19 Vaccine Clinical Trial Moderna MNEXSPIKE
BRIEF published on 05/31/2025 at 06:21, 11 months 13 days ago Le vaccin mNEXSPIKE de Moderna contre la COVID-19 obtient l'approbation de la FDA Essai Clinique Approbation De La FDA Moderne Vaccin Contre Le Covid-19 MNEXSPIKE
PRESS RELEASE published on 05/31/2025 at 06:16, 11 months 13 days ago Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE Moderna's mNEXSPIKE, a new COVID-19 vaccine, receives FDA approval for high-risk age groups. The vaccine shows higher efficacy compared to the original mRNA-1273. Safety profile similar to Spikevax FDA Approval COVID-19 Vaccine Moderna Efficacy MNEXSPIKE
BRIEF published on 05/29/2025 at 00:05, 11 months 15 days ago Moderna Reports Progress and Setback in Avian Flu Vaccine Program Moderna Vaccine Development Phase 1/2 Study H5 Avian Flu MRNA-1018
BRIEF published on 05/29/2025 at 00:05, 11 months 15 days ago Moderna fait état de progrès et de revers dans son programme de vaccination contre la grippe aviaire Développement De Vaccins Moderne Étude De Phase 1/2 Grippe Aviaire H5 ARNm-1018
PRESS RELEASE published on 05/29/2025 at 00:00, 11 months 15 days ago Moderna Announces Update on Investigational Pandemic Influenza Program Moderna's Phase 1/2 H5 avian flu vaccine study shows positive interim results with robust immune response. HHS terminates late-stage development award Moderna Phase 1/2 Study Avian Flu Vaccine H5 Subtype HHS Termination
Published on 05/13/2026 at 08:05, 2 hours 59 minutes ago Tocvan Announces New Surface Gold-Silver Results, Outlining New Target 3 Kilometers East of Main Zone at Gran Pilar Gold-Silver Project
Published on 05/13/2026 at 00:00, 11 hours 4 minutes ago Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
Published on 05/12/2026 at 23:35, 11 hours 29 minutes ago Infield Minerals Closes $1.25 Million Financing
Published on 05/12/2026 at 21:55, 13 hours 9 minutes ago UraniumX Discovery Corp Announces Option Agreement with Gold'n Futures
Published on 05/13/2026 at 10:45, 19 minutes ago EQS-Adhoc: Raiffeisen Bank International AG: RBI intends to increase the offer price for the planned voluntary public tender offer to EUR 26.50 per Addiko share
Published on 05/13/2026 at 10:05, 59 minutes ago H.I.G. Capital Signs Definitive Agreement to Acquire Vitaly Group through its Portfolio Company Avanta Salud
Published on 05/13/2026 at 10:03, 1 hour 1 minute ago Einhell makes a strong start to the 2026 financial year: Power X-Change reaches new all-time high
Published on 05/13/2026 at 10:00, 1 hour 4 minutes ago Zalando appoints ad tech veteran Ray Cao as Senior Vice President to further scale Partner Marketing Services
Published on 05/13/2026 at 10:00, 1 hour 4 minutes ago Ottobock continues strategic expansion of its Patient Care network with acquisition
Published on 05/13/2026 at 10:24, 40 minutes ago Electricité de Strasbourg - Droits de vote au jour de l'avis de réunion de l'AGO du 4 juin 2026
Published on 05/13/2026 at 10:05, 59 minutes ago Guillemot Corporation S.A. | AGM du 04/06/2026 – Mise à disposition des documents préparatoires
Published on 05/13/2026 at 10:05, 59 minutes ago Guillemot Corporation S.A. | CGM of 04/06/2026 – Availability of preparatory documents
Published on 05/13/2026 at 10:00, 1 hour 4 minutes ago Groupe LDC – Organisation d’une visioconférence destinée aux actionnaires et investisseurs particuliers
Published on 05/13/2026 at 06:55, 4 hours 9 minutes ago Recticel Group realiseert doorbraak in PIR circulariteit met gerecycleerde polyol
